Effect of trimetazidine on acute and sub-acute models of inflammation in male wistar rats
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20161519Keywords:
Trimetazidine, Aspirin, Acute, Sub acute, InflammationAbstract
Background: Coronary artery disease (CAD) is the leading cause of morbidity and mortality. Pathogenesis involved in angina pectoris and acute coronary syndrome (ACS) is atherosclerosis. Inflammation drives all phases of atherosclerosis, including initiation, progression of CAD and its complications. Drugs that reduce inflammation may have added benefit in the treatment of cardiovascular disease. Studies have shown that trimetazidine inhibits the inflammatory markers like C- reactive protein, interleukins (IL-1, IL-6) and tumor necrosis factor alpha. Objective of the study was to investigate the effect of trimetazidine on acute and sub-acute models of inflammation in adult male Wistar rats.
Methods: Adult male Wistar rats (150 to 180 mg) were randomly divided into three groups (n=6 each) viz. control (vehicle), aspirin (200 mg / kg body weight of rat) and trimetazidine (5.4 mg / kg body weight of rat). Anti-inflammatory effects of these drugs were studied in acute (carrageenan induced rat paw oedema) and sub-acute (cotton pellet induced granulation tissue and histopathological examination of granulation tissue surrounding grass piths) models of inflammation. Data was expressed as mean±SEM and analysed by one way ANOVA followed by Dunnet’s and Bonferroni test. p<0.05 was considered as significant.
Results: Trimetazidine group showed significant (p <0.05) anti-inflammatory effect both in acute and sub-acute models of inflammation which was comparable to that of aspirin group.
Conclusions: Results of the study indicate that trimetazidine can reduce the complications of atherosclerosis which involves inflammation as the major steps in its pathogenesis.
References
Libby P. The pathogenesis, prevention and treatment of Atherosclerosis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et.al., editors. Harrison`s principles of internal medicine. 18th edition. New York: McGraw Hill; 2008:1983.
National Center for Health Statistics. Detailed diagnoses and procedures: National hospital discharge survey, 1996. Hyattsville: National Center for Health Statistics; 1998; 13: data from Vital and Health Statistics. Available at http://www.cdc.gov/nchs/data/series. Accessed 15 December 2015.
Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(23):III20-6.
Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
Robert FB, Hendiri T, Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target. European Heart Journal Supplements. 2005;7:27-36.
Liuzzo G, Buffon A, Biasucci LM. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation.1998;98:2370-6.
Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by preprocedural treatment with trimetazidine. Tohoku J Exp Med. 2006;208:203-12.
Napoli DP, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart. 2005;91:161-5.
Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22:828-33.
Martins GF, Siqueira AG, Santos JB, Alberto V, Barbara J, Francisca B et al., Trimetazidine and inflammatory response in coronary artery bypass grafting. Ann Card Anaesth. 2009;12(2):127-32.
Katzung BG, Masters SB, Trevor AJ. Vasodilators and treatment of angina pectoris; In: Basic and Clinical Pharmacology. 12th edition. New Delhi: McGraw Hill Publishers; 2009:205-206.
Sharma HL, Sharma KK. Drug therapy of angina pectoris. In: Principles of Pharmacology. 2nd edition. Hyderabad: Paras Medical Publisher; 2011:287.
Konstantinos T, Antonio C, Christodoulos S. Inflammation and restenosis after percutaneous coronary interventions, European Heart Journal. 2004;25:1679-87.
Laurence DR, Bacharach AL. Evaluation of drug activities: pharmacometrics Vol. 2. New York and London: Academic Press Inc; 1964.
Sweetman SC. Martindale The Complete Drug Reference. 36th edition. London: Pharmaceutical Press; 2009:1320,1386,1349,1419.
Vogel GH. Drug Discovery and Evaluation, Pharmacological Assays. 3rd edition. NewYork: Springer-verlag Berlin Heidelberg; 2008:1094-1113.
